Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for receptors tumor necrosis factor, member 14 (compound)
Most Correlated Studies
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Most Relevant Literature
- Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM …
- BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biologica…
- Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular…
- Realigning the LIGHT signaling network to control dysregulated inflammation.
- T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-ex…
Most Relevant Clinical Trials
- Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
- NeoTIL in Advanced Solid Tumors
- Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis
- Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBER…
- Cancer Vaccine Targeting Brachyury Protein in Tumors
